Ikarian Capital’s Enveric Biosciences ENVB Stock Holding History

Ikarian Capital’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25	Closed	-$48K	–	126
2022 Q2	$48K	Sell	25 -22	-47%	-$46.8K	0.01%	135
2022 Q1	$141K	Buy	47 +3	+7%	+$13.3K	0.02%	175
2021 Q4	$372K	Buy	+44	New	+$618K	0.06%	143

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ikarian Capital's ENVB Position: Q3 2022 in Review

Ikarian Capital sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 25 shares — an estimated $48K sold.

Ikarian Capital first reported a position in ENVB in Q4 2021 and held it in 3 quarters. The position peaked at $372K in Q4 2021. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

Ikarian Capital reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 25 Enveric Biosciences shares in Q3 2022, an estimated $48K.
Ikarian Capital first reported a position in Enveric Biosciences in Q4 2021 and held it in 3 quarters.
Ikarian Capital's Enveric Biosciences position peaked at $372K in Q4 2021.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.